Mirtazapine-d₃

Mirtazapine-d₃ is intended for use as an internal standard for the quantification of mirtazapine by GC- or LC-MS. Mirtazapine is a tetracyclic antidepressant.¹ It selectively binds to the histamine H₁ receptor, α_2A- and α_2C-adrenergic receptors, and the serotonin (5-HT) receptor subtypes 5-HT_2A and 5-HT_2C (K_is = 1.6, 20, 18, 69, and 39 nM, respectively) over the α₁-adrenergic receptor, 5-HT₇, norepinephrine transporter (NET), and dopamine D₁, -D₂, and -D₃ receptors (K_is = 608, 265, 1,640, 4,167, >5,454, and 5,723 nM, respectively). Mirtazapine inhibits tryptamine-induced cyanosis, bilateral convulsions, and backward locomotion in rats (ED₅₀s = 0.8, 0.32, and 0.5 mg/kg, respectively). It prevents the acquisition and reinstatement of cocaine-induced place preference in rats.² Mirtazapine (40 mg/kg) decreases immobility time in the forced swim test in mice.³ Formulations containing mirtazapine have been used in the treatment of major depressive disorder. This product is also available as an analytical reference standard (Item Nos. 31762 | 21126).

WARNING This product is not for human or veterinary use.

1. Fernández, J., Alonso, J.M., Andrés, J.I., et al. Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J. Med. Chem. 48(6), 1709-1712 (2005).

2. Barbosa-Méndez, S., Matus-Ortega, M., Jacinto-Gutiérrez, S., et al. Mirtazapine impairs acquisition and reinstatement of cocaine-induced place preference in rats. Eur. J. Pharmacol. 820, 183-190 (2018).

3. Muguruza, C., Rodríguez, F., Rozas, I., et al. Antidepressant-like properties of three new α2-adrenoceptor antagonists. Neuropharmacology 65, 13-19 (2013).